Anna Barry
UCB Pharma
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anna Barry as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:18 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00383214 · Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)UCB Pharma · terminated · Systemic Lupus Erythematosus · study director
- Ph3NCT00382837 · Study of Epratuzumab in Systemic Lupus ErythematosusUCB Pharma · withdrawn · Systemic Lupus Erythematosus · study director
- Ph2NCT00113971 · Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)UCB Pharma · terminated · Lupus Erythematosus, Systemic · study director
- Ph3NCT00111306 · Study of Epratuzumab in Systemic Lupus ErythematosusUCB Pharma · terminated · Systemic Lupus Erythematosus · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:18 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- CPR quality improvement during in-hospital cardiac arrest using a real-time audiovisual feedback system.Resuscitation · 2007278 citationsRCR 9.8
- Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.Antimicrob Agents Chemother · 1995274 citationsRCR 11.4
- 267 citationsRCR 8.5
- PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.Lancet Infect Dis · 2020106 citationsRCR 5.3
- Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.Rheumatology (Oxford) · 201397 citationsRCR 2.9
- Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial.Clin Infect Dis · 201592 citationsRCR 4.0
- Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.J Pain Symptom Manage · 200273 citationsRCR 2.6
- First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.PLoS One · 201854 citationsRCR 2.0
- Effects of helium-neon laser irradiation on skin resistance and pain in patients with trigger points in the neck or back.Phys Ther · 198949 citationsRCR 3.9
- 46 citationsRCR 1.6